Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Edesa Biotech, Inc. - Common Shares
(NQ:
EDSA
)
5.847
+0.197 (+3.49%)
Streaming Delayed Price
Updated: 9:30 AM EDT, Aug 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Edesa Biotech, Inc. - Common Shares
< Previous
1
2
3
4
5
6
Next >
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
↗
December 23, 2022
Gainers
Via
Benzinga
FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate
December 20, 2022
Via
ACCESSWIRE
Edesa Biotech Reports Fiscal Year 2022 Results
December 16, 2022
Via
ACCESSWIRE
Edesa Biotech Adds Mechanically Ventilated Patients To Late-Stage COVID-19 Study
↗
May 24, 2022
Via
Benzinga
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session
↗
December 22, 2022
Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference
December 02, 2022
Via
ACCESSWIRE
Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market
November 03, 2022
Via
ACCESSWIRE
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
↗
October 03, 2022
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.
Via
Benzinga
What Is Going on With Edesa Biotech (EDSA) Stock Today?
↗
September 30, 2022
Edesa Biotech released encouraging Phase 2 results for its respiratory-syndrome-targeting antibody, thus initially boosting EDSA stock.
Via
InvestorPlace
Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study
September 30, 2022
Via
ACCESSWIRE
Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference
September 08, 2022
Via
ACCESSWIRE
Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment
September 07, 2022
Via
ACCESSWIRE
Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results
August 12, 2022
Via
ACCESSWIRE
Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference
August 03, 2022
Via
ACCESSWIRE
Edesa Biotech to Present at ARDS Drug Development Summit
July 11, 2022
TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par...
From
Edesa Biotech
Via
AccessWire
Stocks That Hit 52-Week Lows On Tuesday
↗
June 28, 2022
On Tuesday, 87 companies hit new 52-week lows.
Via
Benzinga
Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study
May 24, 2022
TORONTO, ON / ACCESSWIRE / May 24, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the...
From
Edesa Biotech
Via
AccessWire
Edesa Biotech to Present at H.C. Wainwright Global Investment Conference
May 19, 2022
TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par...
From
Edesa Biotech
Via
AccessWire
Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results
May 13, 2022
TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial...
From
Edesa Biotech
Via
AccessWire
Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected
April 28, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Edesa Biotech
Via
AccessWire
Edesa Biotech Appoints Strategy Expert to Board of Directors
March 29, 2022
TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the...
From
Edesa Biotech
Via
AccessWire
Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering
March 24, 2022
TORONTO, ON / ACCESSWIRE / March 24, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the...
From
Edesa Biotech
Via
AccessWire
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 22, 2022
TORONTO, ON / ACCESSWIRE / March 22, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it...
From
Edesa Biotech
Via
AccessWire
Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study
February 17, 2022
TORONTO, ON / ACCESSWIRE / February 17, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an...
From
Edesa Biotech
Via
AccessWire
66 Biggest Movers From Yesterday
↗
March 23, 2022
Gainers JX Luxventure Limited (NASDAQ: LLL) shares jumped 119.5% to settle at $4.39 on Tuesday after the company announced it signed a $60 million sales agreement. Forge Global...
Via
Benzinga
Edesa Biotech Reports Fiscal 1st Quarter 2022 Results
February 14, 2022
TORONTO, ON / ACCESSWIRE / February 14, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported...
From
Edesa Biotech
Via
AccessWire
Edesa Biotech to Join Ontario Bioscience Panel Discussion
January 26, 2022
TORONTO, ON / ACCESSWIRE / January 26, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr....
From
Edesa Biotech
Via
AccessWire
Canada Approves Edesa Biotech's COVID-19 Trial For EB05 Antibody As Rescue Therapy
↗
January 13, 2022
Health Canada has approved to test Edesa Biotech Inc's (NASDAQ: EDSA) monoclonal antibody candidate, designated EB05, as COVID-19 rescue therapy for critically...
Via
Benzinga
Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy
January 13, 2022
- Phase 3 study will focus on critically ill patients, many of whom have run out of effective drug treatment options TORONTO, ON / ACCESSWIRE / January 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a...
From
Edesa Biotech
Via
AccessWire
5 Stocks To Watch For Wednesday, December 29, 2021
↗
December 29, 2021
5 stocks you that you should keep in mind today.
Via
Talk Markets
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
